Candriam S.C.A. Buys 341,431 Shares of Annexon, Inc. (NASDAQ:ANNX)

Candriam S.C.A. lifted its stake in Annexon, Inc. (NASDAQ:ANNX) by 15.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,534,230 shares of the company’s stock after purchasing an additional 341,431 shares during the period. Candriam S.C.A. owned 2.38% of Annexon worth $13,001,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. FMR LLC raised its stake in Annexon by 3.2% during the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after buying an additional 262,229 shares during the period. State Street Corp raised its stake in Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after buying an additional 2,068,294 shares during the period. Geode Capital Management LLC raised its stake in Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after buying an additional 331,269 shares during the period. JPMorgan Chase & Co. raised its stake in Annexon by 16.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after buying an additional 235,810 shares during the period. Finally, Sio Capital Management LLC acquired a new stake in Annexon during the 3rd quarter worth $8,484,000.

Annexon Price Performance

ANNX opened at $2.76 on Friday. The business’s 50-day moving average price is $3.75 and its two-hundred day moving average price is $5.34. Annexon, Inc. has a 1 year low of $2.30 and a 1 year high of $8.40. The company has a market capitalization of $294.20 million, a price-to-earnings ratio of -2.63 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Sell-side analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANNX has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $15.80.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.